Artios Pharma Ltd., the Cambridge, UK-based biotech focusing on the DNA damage response (DDR) to develop first-in-class cancer treatments, has raised £65 million ($83 million) in a series B round led by Andera Partners (formerly EdRIP) and LSP (Life Science Partners) alongside new investors Novartis Venture Fund and Pfizer Ventures and existing shareholders Arix Bioscience, SV Health Investors, M Ventures, IP Group and Abbvie Ventures.
Artios Pharma Hooks Novartis & Pfizer In Over-Subscribed £65M Series B Round
With DNA damage repair pathways attracting a lot of attention as potential targets against various cancers, three-year old Artios Pharma has raised £65 million in an over-subscribed Series B round to fund the clinical development of its pipeline through to 2023.
More from Financing
More from Business
• By
A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.
• By
Adstiladrin sales hit €70m in first full year on the market
• By
Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.